Adrenomed supports the #DeutschlandErkenntSepsis campaign initiated by Aktionsbündnis Patientensicherheit and supported by Sepsis Stiftung, Sepsisdialog and Deutsche Sepsis-Hilfe. The campaign’s goal is to raises awareness of sepsis and to improve recognition, diagnosis, and treatment of sepsis. In Germany only, every seven minutes someone dies from sepsis.
At Adrenomed, we are developing Adrecizumab (HAM8101): a clinical-stage, first-in-class monoclonal antibody, targeting the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity, to treat sepsis and other life-threatening conditions associated with increased vascular leakage, congestion, and shock. Adrecizumab successfully concluded a Phase 2 clinical trial in 301 patients with septic shock. https://www.deutschland-erkennt-sepsis.de